Stratec Biomedical AG (SBS) Given a €57.00 Price Target by Berenberg Bank Analysts
Stratec Biomedical AG (ETR:SBS) has been assigned a €57.00 ($67.06) price objective by analysts at Berenberg Bank in a research note issued on Monday. The brokerage currently has a “neutral” rating on the stock.
A number of other research firms have also weighed in on SBS. Deutsche Bank AG set a €55.00 ($64.71) target price on Stratec Biomedical AG and gave the stock a “neutral” rating in a report on Thursday, July 27th. Kepler Capital Markets set a €66.00 ($77.65) price objective on Stratec Biomedical AG and gave the company a “buy” rating in a report on Wednesday, July 26th. Warburg Research set a €62.00 ($72.94) price objective on Stratec Biomedical AG and gave the company a “buy” rating in a report on Tuesday, July 25th. Finally, Oddo Securities set a €58.00 ($68.24) price objective on Stratec Biomedical AG and gave the company a “neutral” rating in a report on Monday, July 24th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of €59.60 ($70.12).
Shares of Stratec Biomedical AG (SBS) opened at 57.122 on Monday. Stratec Biomedical AG has a 52 week low of €41.45 and a 52 week high of €63.18. The firm has a market cap of €679.07 million and a P/E ratio of 35.282. The stock has a 50 day moving average of €53.11 and a 200 day moving average of €55.23.
About Stratec Biomedical AG
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.
Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.